ProtoKinetix

ProtoKinetix Net Change in Cash

The Net Change in Cash of ProtoKinetix (PKTX) as of Nov 19, 2026 is 5,815.00 USD. In the previous year, Net Change in Cash was -25,105.00 USD — a change of -123.16% (higher).

Net Change in Cash

5,815.00USD

YoY

-123.16%

Last updated:

Net Change in Cash of ProtoKinetix is 2025 5,815.00 USD. Net Change in Cash of ProtoKinetix was 2024 -25,105.00 USD. It decreases by -123.16% higher compared to the previous year.

The ProtoKinetix Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-166,913.00 USD
Jan 1, 2019
241,320.00 USD
Jan 1, 2020
-183,905.00 USD
Jan 1, 2021
-135,877.00 USD
Jan 1, 2022
-32,018.00 USD
Jan 1, 2023
-5,142.00 USD
Jan 1, 2024
-25,105.00 USD
Jan 1, 2025
5,815.00 USD
The ProtoKinetix Net Change in Cash history
YEARNet Change in CashYoY
5,815.00USD-123.16%
-25,105.00USD+388.23%
-5,142.00USD-83.94%
-32,018.00USD-76.44%
-135,877.00USD-26.12%
-183,905.00USD-176.21%
241,320.00USD-244.58%
-166,913.00USD+145.15%
-68,087.00USD+158,241.86%
-43.00USD-100.01%
370,755.00USD-13,591.81%
-2,748.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Net Change in Cash of ProtoKinetix is 5,815.00 USD in 2025.

Net Change in Cash of ProtoKinetix changed from -25,105.00 USD to 5,815.00 USD, representing a -123.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ProtoKinetix

All Key Metrics — ProtoKinetix